gene in people relapsing after treatment Together with the BCL2 antagonist venetoclax. sixty six Resistance to those brokers has become associated with these mutations in about 70% of cases, Whilst they are often subclonal as well as their specific purpose causing resistance ought to be confirmed.Genetic susceptibility mechanisms. Most susceptibili